cardiovascular drugs

MSD Licenses Cardiovascular Drug from Hengrui Pharma

MSD (Merck & Co.) and Hengrui Pharma recently announced that they have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor.

Medera to Go Public through Merger with KVAC

Keen Vision Acquisition Corp. (KVAC) and Medera, a clinical-stage biotechnology company, have entered into a merger agreement. Upon closing of the merger, which is expected to occur in the fourth quarter of 2024, the combined company will operate under the name Medera.

Roche Suffers Diabetes Drug Setback

Roche Gives Up on Heart Drug after Trial Disappoints